All In Biotech

NDA 021456 · Eisai Medcl Res

Aciphex

Rabeprazole Sodium · Oral

Last checked: Nov 20, 2026Latest source record: Nov 8, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Nov 8, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

260

41 Phase 3, 12 recruiting

FAERS reports

27,290

21,997 serious, 3,391 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 8, 2002 Original approval · Type 6 - New Indication (no longer used) LabelLetterReview
1 products under this application
  • ACIPHEX · RABEPRAZOLE SODIUM 20MG · Tablet, Delayed Release, Oral · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rabeprazole" as an intervention, any sponsor and status, largest first.

All 260 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease4,878
  • renal failure3,417
  • acute kidney injury2,629
  • nausea1,646
  • drug ineffective1,579
  • end stage renal disease1,310
  • diarrhoea1,203
  • dyspnoea1,196
  • pain1,189
  • headache1,130
  • death1,128
  • tubulointerstitial nephritis1,122

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,025
20051,068
20061,064
2007958
20081,000
2009914
20101,179
20111,674
20121,874
2013663
2014602
2015712
2016745
2017654
20185,997
20191,359
2020726
2021888
20221,122
2023945
2024892
2025736
2026492

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aciphex (Rabeprazole Sodium)

2024 spending

$16.4M

Beneficiaries

1,549

6,163 claims

Per beneficiary

$10,584

$29.03 per unit

View as table
YearSpending
2020$0
2021$0
2022$4,515,854
2023$15,631,965
2024$16,394,805

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 545 on PubMed

Sponsor: Eisai

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.